GlassScriptPhysician profile
Grace I Wong
NPI 1053504902
$2,306.98
in general payments reported to CMS, 2019-2025
27 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $57.48 · 2021: $233 · 2022: $171 · 2023: $519 · 2024: $743 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.13 | 2021-2024 | Vraylar |
| Amgen INC. | $254.83 | 2023-2025 | Repatha, Otezla |
| Novo Nordisk INC | $218.24 | 2021-2025 | Ozempic, Rybelsus, Saxenda |
| Glaxosmithkline, LLC. | $160.07 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $155.98 | 2024 | Voquezna |
| Shield Therapeutics INC | $148.03 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.38 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $95.21 | 2023-2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $65.93 | 2023 | |
| Alkermes, INC. | $65.58 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $63.71 | 2023-2025 | Contrave |
| Astellas Pharma US INC | $60.31 | 2021 | |
| Pfizer INC. | $56.03 | 2022-2024 | |
| Dynasplint Systems INC. | $51.11 | 2025 | Dynasplint |
| Phadia US INC. | $51.04 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $46.89 | 2024-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $43.58 | 2019-2023 | Aptima, Thinprep 2000 Processor |
| Lilly USA, LLC | $41.56 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $41.38 | 2023-2024 | Xarelto |
| Alfasigma USA, INC. | $38.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.06 | 2019-2021 | |
| Inspire Medical Systems, INC. | $27.79 | 2025 | Inspire |
| Viiv Healthcare Company | $22.39 | 2024 | Apretude |
| Merck Sharp & Dohme LLC | $20.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.58 | 2024 | |
| Medline Industries LP | $18.15 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.